2018-12-14T17:35:07-06:00 2018-03-31 ERNST & YOUNG US LLP 1901 6TH AVE N BIRMINGHAM AL 35203 990 2017-04-01 751835298 SUSAN G KOMEN BREAST CANCER FDN INC % RIA WILLIAMS SUSA 9728551600 5005 LBJ Freeway suite 526 Dallas TX 752446125 PAULA SUE SCHNEIDER PRESIDENT AND CEO 9728551600 2018-12-14 KATHY PITTS P00292940 2052260027 97.77.198.2 75306120183485000015 2018-12-14 P EFEC630553F7A05BD707F6467E755DCD1324F206 69C071E2F2C5E195884386C1B3C530989D25512E 2017 2019-02-21 02:37:17Z Susan G Komen Paula Sue Schneider 5005 LBJ Freeway Suite 526 Dallas TX 752446125 109982784 false 7164 X www.komen.org X 1982 TX OUR MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER. 14 14 245 2640 6100 -14562 55634984 51441732 15856597 14437717 3758190 14239081 -4906867 -3380561 70342904 76737969 35357025 28995790 0 0 24717739 21442628 2584720 1118493 11817989 36543700 31719529 99203184 83276440 -28860280 -6538471 220522141 201811514 92137738 77405059 128384403 124406455 X SUSAN G. KOMEN's MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER. false false 32 34254506 26025613 14437717 GRANTS TO ACADEMIC INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON THE BIOLOGY OF BREAST CANCER; EARLY DETECTION, DIAGNOSIS, AND PREVENTION STRATEGIES; DEVELOPING TARGETED THERAPIES, OVERCOMING BREAST CANCER PROGRESSION, TREATMENT RESISTANCE AND METASTASIS, PREDICTING RISK, DEVELOPING NEW IMAGING TECHNIQUES, AND UNDERSTANDING AND ADDRESSING DISPARITIES IN OUTCOMES AS WELL AS RESEARCH RESOURCES AND CONFERENCES. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 32 23555222 555547 0 PROVISION OF BREAST HEALTH/CANCER EDUCATION MATERIALS AND PATIENT SUPPORT PROGRAMS, SUCH AS THE KOMEN BREAST CARE HELPLINE, CLINICAL TRIAL INFORMATION HELPLINE, AND TREATMENT ASSISTANCE PROGRAM, WERE MADE POSSIBLE DIRECTLY BY KOMEN AND THROUGH GRANTS TO OTHER NONPROFIT ORGANIZATIONS TO INCREASE THE PUBLIC'S KNOWLEDGE OF BREAST CANCER, ITS RISK FACTORS, THE IMPORTANCE OF EARLY DETECTION, METASTATIC BREAST CANCER, TREATMENT, SOCIAL SUPPORT, AND INFORMATION ABOUT COMMUNITY RESOURCES. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 32 5917427 2414630 1387402 GRANTS TO OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS WITH A SPECIAL EMPHASIS ON PATIENT NAVIGATION, ESPECIALLY IN COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 63727155 true true false true false false false false false true true true false false false true false true false false true true false true true false false true false true false false false false false false false false true false false false false false false false false true 71 0 true 245 true true true false false false false true true false false false false X 14 14 false false false false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X RIA WILLIAMS 9728551600 5005 LBJ Freeway Suite 526 Dallas TX 75244 Connie O'Neill Chair of the Board 1.0 0.0 X X 0 0 0 Linda Custard BOARD MEMBER 1.0 0.0 X 0 0 0 Jane Abraham BOARD MEMBER 1.0 0.0 X 0 0 0 Alan Feld BOARD MEMBER 1.0 0.0 X 0 0 0 Dr Olufunmilayo Olopade BOARD MEMBER 1.0 0.0 X 0 0 0 Janet Dunn Frantz BOARD MEMBER 1.0 0.0 X 0 0 0 Dan Glennon BOARD MEMBER and Treasurer 1.0 0.0 X X 0 0 0 Melissa Maxfield BOARD MEMBER 1.0 0.0 X 0 0 0 Meghan Shannon BOARD MEMBER 1.0 0.0 X 0 0 0 Trish Wheaton BOARD MEMBER 1.0 0.0 X 0 0 0 Angela Zepeda BOARD MEMBER 1.0 0.0 X 0 0 0 Kim Bohr BOARD MEMBER (Beg. 6/17) 1.0 0.0 X 0 0 0 Peter D Brundage BOARD MEMBER (Beg. 6/17) 1.0 0.0 X 0 0 0 Andrew Robinson BOARD MEMBER (Beg. 6/17) 1.0 0.0 X 0 0 0 Linda Wilkins BOARD MEMBER (End 6/17) 1.0 0.0 X 0 0 0 Kaye Ceille BOARD MEMBER (End 6/17) 1.0 0.0 X 0 0 0 Paula Schneider President and CEO (Beg. 10/17) 55.0 0.0 X 137155 0 6155 Robert Green Chief Financial Officer 55.0 0.0 X 284384 0 10809 Adam Vanek BEG 417 Gen. Counsel & Asst Corp Secy 55.0 0.0 X 166163 0 23926 Ellen Willmott INTERIM CEO (END 10/17) 55.0 0.0 X 380456 0 26839 Lesley Lurie END 417 Deputy Counsel & Assist Secy 55.0 0.0 X 95097 0 16737 Christina Alford SVP, Development 55.0 0.0 X 282288 0 19315 Victoria Wolodzko VP Research and Com. Health Pr 55.0 0.0 X 185526 0 21607 Lori Maris SVP, Affiliate Network 55.0 0.0 X 170432 0 18785 Eric Montgomery VP, I.T. 55.0 0.0 X 194143 0 46653 Catherine Olivieri VP, Human Resources 55.0 0.0 X 218036 0 52214 Andrea Rader Sr Dir, Com. (End 04/18) 55.0 0.0 X 172769 0 28449 Ria Williams Controller 55.0 0.0 X 172059 0 42500 Subhendu Rath Sr Dir, IT Enterprise Systems 55.0 0.0 X 164799 0 28697 Vanessa Hewitt Sr Dir, Internal Audit 55.0 0.0 X 158438 0 30560 Kimberly Sabelko Sr Dir, Scientific Strategy 55.0 0.0 X 154755 0 30281 Dr Judith Salerno Former President & CEO 0.0 0.0 X 271623 0 0 3208123 0 403527 49 true true false Event 360 205 N Michigan Ave CHICAGO IL 60601 Event Management 6169963 Stephen Thomas Ltd 184 FRONT STREET EAST SUITE 501 TORONTO ONTARIO CA M5A 4N3 Direct Marketing SS 1236588 The Advertising Council Inc 815 Second Avenue 9th floor NEW YORK NY 10017 Marketing 649147 Blackbaud Inc PO Box 930256 ATLANTA GA 311930256 Donation Software Ss 583144 Laurel Strategies Inc 4A Oxford Street CHEVY CHASE MD 20815 Consulting 520000 19 359104 16005958 35076670 226197 51441732 Affiliate Research funds 900099 14437717 14437717 0 0 14437717 5589970 5589970 0 77303 77303 0 0 0 36121988 27472877 8649111 8649111 8649111 723932 16005958 5693721 -4969789 -4969789 0 0 0 0 16300 78217 -61917 -61917 SHARED SERVICES INTERCOMPANY 900099 1449319 1449319 0 0 Other Income 900099 124523 0 6100 118423 1573842 76737969 15825119 6100 9465018 X 26648984 26648984 0 0 2346806 2346806 0 0 2385305 1518488 524165 342652 0 0 0 0 15494732 9844534 3409690 2240508 697170 450252 143152 103766 1790058 1117213 415564 257281 1075363 679564 243794 152005 0 0 0 0 152020 71797 24793 55430 451550 265925 93057 92568 210678 210678 0 0 1118493 1118493 69358 0 69358 0 0 0 0 0 1954534 1277995 101529 575010 9016836 5380940 104276 3531620 1638065 1249384 160872 227809 0 0 0 0 965029 606865 177043 181121 1335480 775872 470989 88619 0 0 0 0 262622 201420 61202 0 0 0 0 0 0 0 0 0 587266 275331 246241 65694 364269 214524 75070 74675 Consult & Prof. Svcs 10117705 8215278 446132 1456295 Equip Rental & Maint 1535239 863996 285647 385596 Event Production 1472174 870165 371078 230931 Bank fees 919608 381253 64922 473433 667096 259891 242722 164483 83276440 63727155 7731296 11817989 X 24611074 10238777 1438841 12933456 0 0 31823756 31040869 20419320 15710504 3718830 2934675 0 0 0 0 0 0 102613 209655 1176543 1215980 9239331 8071129 1639690 1168202 97151712 101757276 64468904 47753580 0 0 0 0 20773 20773 220522141 201811514 8991250 6873683 82800353 70283876 346135 247500 0 0 0 0 0 0 0 0 0 0 0 0 92137738 77405059 X 83312668 86358517 44746735 37722938 325000 325000 128384403 124406455 220522141 201811514 X -6538471 -228854 -244500 0 0 3033877 X false true X true false X 91606572 77337857 105234559 55634984 51441732 381255704 0 0 91606572 77337857 105234559 55634984 51441732 381255704 37715158 343540546 4064746 3542123 2523145 2265964 5667273 18063251 0 0 0 0 0 0 436740 153632 336857 51821 124523 1103573 400422528 103084467 0.85794 0.86153 X X 10245 19478 200433 234047 210678 253525 75334466 153056366 75545144 153309891 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 91934 218796 274215 253525 838470 250000 250000 250000 250000 1000000 1500000 52478 66033 19341 19478 157330 Lobbying Expenses SCHEDULE C, PART II-A PUBLIC POLICY INITIATIVES HAVE THE POTENTIAL TO IMPACT PEOPLE TOUCHED BY BREAST CANCER. RECOGNIZING THE POWER OF ADVOCACY TO ACCOMPLISH ITS MISSION, KOMEN SUPPORTS LIMITED LOBBYING ACTIVITIES TO ACHIEVE EVIDENCE-BASED POLICY AND LEGISLATIVE SOLUTIONS DESIGNED TO END BREAST CANCER FOREVER. 1377855 0 10034 0 25799 0 1362090 1376069 1786 0 1377855 1346721 29808 460 1376069 1346267 4717 4263 1346721 1325000 0 23736 2469 1346267 0.73000 0.24000 0.03000 false false 0 610067 225951 384116 2283342 2099946 183396 6345922 5745232 600690 1168202 Long/short equity fund 1165580 F Private equity fund 46588000 F 47753580 0 0 X INTENDED USE OF ENDOWMENT FUNDS SCHEDULE D, PART V, LINE 4 KOMEN HAS THREE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, AND A GENERAL ENDOWMENT. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, AND THE GENERAL ENDOWMENT'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES. FIN 48 (ASC740) FINANCIAL STATEMENT DISCLOSURE SCHEDULE D, PART X, LINE 2 THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2018 OR MARCH 31, 2017. true Central America and the Caribbean 0 2 Grantmaking Education 68416 Central America and the Caribbean 0 1 Grantmaking Screening 45000 East Asia and the Pacific 0 2 Grantmaking Research 269871 Europe (Including Iceland and Greenland) 0 9 Grantmaking Research 1054471 Middle East and North Africa 0 3 Grantmaking Education 21841 North America 0 5 Grantmaking Research 672834 North America 0 2 Grantmaking Screening 61239 South America 0 1 Grantmaking Education 53500 South America 0 1 Grantmaking Screening 55000 South America 0 1 Grantmaking Treatment 34880 Sub-Saharan Africa 0 1 Grantmaking Education 9754 Europe (Including Iceland and Greenland) 0 4 Program Services Program Support 16677 North America 0 7 Program Services Program Support 69529 North America 0 1 Program Services Direct Mail Processing 9080694 North America 0 2 Program Services Marketing Support 192216 North America 0 1 Program Services Software Maintenance 4577 South America 0 2 Program Services Program Support 43405 Sub-Saharan Africa 0 3 Program Services Program Support 23581 0 45 0 3 0 48 11753904 23581 11777485 North America Screening Education Education Research Education Education Research Research Screening Research Research Screening Screening Research Research Research Treatment Research Education Research Research Education Research Education Research Research Research Research EDUCATION, TREATMENT RESEARCH RESEARCH, SCREENING, EDUCATION TREATMENT EDUCATION RESEARCH SCREENING, TREATMENT RESEARCH RESEARCH EDUCATION, TREATMENT RESEARCH SCREENING, TREATMENT RESEARCH RESEARCH EDUCATION, TREATMENT EDUCATION EDUCATION EDUCATION, TREATMENT RESEARCH RESEARCH RESEARCH RESEARCH RESEARCH RESEARCH EDUCATION, SCREENING, TREATMENT RESEARCH RESEARCH EDUCATION RESEARCH TREATMENT EDUCATION RESEARCH EDUCATION, RESEARCH RESEARCH RESEARCH EDUCATION RESEARCH RESEARCH RESEARCH RESEARCH RESEARCH RESEARCH RESEARCH TREATMENT RESEARCH RESEARCH EDUCATION, RESEARCH EDUCATION RESEARCH EDUCATION, RESEARCH EDUCATION EDUCATION RESEARCH RESEARCH RESEARCH RESEARCH RESEARCH RESEARCH EDUCATION, RESEARCH EDUCATION EDUCATION, SCREENING R 59241 Wire Transfe Central America and the Caribbean Screening 28416 Wire Transfe Middle East and North Africa Research 10000 Wire Transfe North America Treatment 50000 Wire Transfe South America Education 53500 Wire Transfe Sub-Saharan Africa Research 9754 Wire Transfe Europe (including Iceland and Greenland) Screening 35640 Wire Transfe Europe (including Iceland and Greenland) Education 35000 Wire Transfe South America Research 55000 Wire Transfe Europe (including Iceland and Greenland) Research 30000 Wire Transfe Europe (including Iceland and Greenland) Education 120000 Wire Transfe Central America and the Caribbean Research 45000 Wire Transfe East Asia and the Pacific Research 149871 Wire Transfe Europe (including Iceland and Greenland) Research 148128 Wire Transfe Europe (including Iceland and Greenland) Treatment 60000 Wire Transfe South America Education 34880 Wire Transfe Europe (including Iceland and Greenland) Education 190703 Wire Transfe Middle East and North Africa Education 6500 Wire Transfe North America Research 190000 Wire Transfe Europe (including Iceland and Greenland) Research 135000 Wire Transfe Central America and the Caribbean Research 40000 Wire Transfe North America Research 149320 Wire Transfe Middle East and North Africa Research 5341 Wire Transfe North America Research 55121 Wire Transfe East Asia and the Pacific Research 120000 Wire Transfe North America Research 228394 Wire Transfe Europe (including Iceland and Greenland) Education, Screening Treatment 300000 Wire Transfe 28 false false true false false false PROCEDURES FOR MONITORING USE OF GRANT FUNDS OUTSIDE OF THE UNITED STATES SCHEDULE F, PART I, LINE 2 AS OUTLINED IN EACH GRANT AGREEMENT, ALL GRANTEES ARE REQUIRED TO SUBMIT, AT A MINIMUM, ONE FINANCIAL AND PROGRESS REPORT WITHIN EACH YEAR OF THE GRANT TERM, AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV FOR MORE DETAILS. X X X X X X true Event 360 Fundraising Consulting false 15672171 380000 15292171 Stephen Thomas LTD 184 Front Street East Suite 501 Toronto Ontario CA M5A 4N3 Direct Marketing false 14447032 464592 13982441 Infinite Agency PO Box 51706 Lafayette LA 70505 Marketing Consulting false 1326000 126522 1199478 Artsmarketing Svcs Inc 260 King Street East Suite 500 Toronto Ontario CA M5A4L5 Telemarketg false 111220 63412 47808 Merkle Inc 100 Jamison Court Hagerstown MD 21740 Direct Marketing false 49105 Bob Carter Companies 400 Madison Drive Suite 204 Sarasota FL 34236 Fundraising Consulting false 34862 31556423 1118493 30521898 AL AK AZ AR CA CO CT DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY 3 Day 14764958 14403799 361159 0 31735 950464 720176 3503257 DC Race 724107 533484 190623 0 57402 34256 125503 3 1240825 1068675 172150 0 1787 86612 112000 47090 23439 16729890 16005958 723932 0 33522 1094478 866432 47090 3652199 5693721 -4969789 NET INCOME SUMMARY SCHEDULE G PART II Gross receipts are reduced by the amount of contributions, per IRS instructions. The contributions for fiscal year 2018 were $16,005,958. true African Women's Cancer Awareness Assoc 8955 Edmonston Road Greenbelt MD 20770 731704355 501(C)(3) 57004 Research Albany Medical College Attn Frances Albert Albany NY 12208 141338310 501(C)(3) 150000 Education American Association for Cancer Research 615 Chestnut Street 17th Fl Philadelphia PA 191064404 236251649 501(C)(3) 328000 Research American Association on Health & Disabil 110 N Washington StreetSuite 328J Rockville MD 20850 521884887 501(C)(3) 44165 Education American Jewish Joint Attn Itai Shamir New York NY 100174014 131656634 501(C)(3) 112500 Research American Society of Clinical Oncology Conquer Cancer Foundation Alexandria VA 22314 136180880 501(C)(3) 100000 Research Arlington Free Clinic 2921 11th Street South Arlington VA 22204 541671883 501(C)(3) 59959 Research Baylor College Medicine Grants - Accounts Receivable Houston TX 770303411 741613878 501(C)(3) 951217 Education Beth Israel Deaconess Medical Center Research Finance Office BR109 Boston MA 02215 042103881 501(C)(3) 162000 Research Boat People SOS 6066 Leesburg Pike 100 Falls Church VA 220412220 541563619 501(C)(3) 65327 Treatment Boston University 580 Harrison Avenue 3-W Boston MA 02118 042103547 501(C)(3) 108000 Research Breast Care for Washington 4 Atlantic St SW Washington DC 20032 455574713 501(C)(3) 60000 Research Brigham & Women's Hospital PO Box 3149 Boston MA 022413149 042312909 501(C)(3) 323929 Research Broad Institute Inc 415 Main Street Cambridge MA 02142 263428781 501(C)(3) 122996 Research Cancer Care 275 Seventh Avenue New York NY 10001 131825919 501(C)(3) 1439879 Education Cancer Resource Centers of Mendocino Cty 45040 Calpella Street Mendocino CA 95460 680357416 501(C)(3) 13108 Research Capital Breast Care Center 3970 Reservoir Road NW Washington DC 200571468 530196603 501(C)(3) 50000 Research CASA of Maryland Inc Attn Jennifer Freedman Hyattsville MD 20783 521372972 501(C)(3) 35000 Research Case Western Reserve University Controllers Office Cleveland OH 441067006 341018992 501(C)(3) 294311 Education Children's Hospital Boston Research Finance Boston MA 022414413 042774441 501(C)(3) 108000 Research Cold Spring Harbor Laboratory Attn Walter Goldschmidts Cold Spring Harbor NY 11724 112013303 501(C)(3) 168000 Education, Research Columbia University Medical Center 722 West 168th Street 4th Floor New York NY 10032 135598093 501(C)(3) 646000 Education Cornell University Attn Ilene Lambiase Ithaca NY 14850 150532082 501(C)(3) 48000 Screening Dana Farber Cancer Institute 44 Binney Street Mail Stop 439C Boston MA 02115 042263040 501(C)(3) 1994658 Education, Screening, Treatment Doctors Community Hospital 8118 Good Luck Road Lanham MD 207063502 521638026 501(C)(3) 75000 Research Dr Susan Love Research Foundation 2811 Wilshire Blvd Santa Monica CA 90403 770009065 501(C)(3) 25000 Research Duke University Medical Center PO Box 602651 Charlotte NC 282602651 560532129 501(C)(3) 536052 Research Eastern Michigan University Attn Susan Shipley Ypsilanti MI 48197 382953297 501(C)(3) 225074 Research Emory University Winship Cancer Inst PO Box 935084 Atlanta GA 311935084 580566256 501(C)(3) 150000 Research Ethiopian Community Development Council Attn Azeb Tadesse Arlington VA 22204 521308986 501(C)(3) 50000 Education Facing Our Risk of Cancer Empowered 16057 Tampa Palms Blvd W 373 Tampa FL 33647 650927702 501(C)(3) 6000 Education, Research Fox Chase Cancer Center 333 Cottman Avenue Philadelphia PA 19111 232003072 501(C)(3) 150000 Education Fred Hutchinson Cancer Research Center PO Box 19024 Mailstop J6-330 Seattle WA 981091024 563744111 501(C)(3) 334998 Education, Screening George Mason University 4400 University Drive MSN 4C6 Fairfax VA 22030 540836354 501(C)(3) 29686 Research George Washington University Grants and Contracts Accounting Svc Ashburn VA 20147 530196584 501(C)(3) 44653 Education, Screening, Treatment Georgetown U Attn Jemas Reisert Washington DC 200571164 530196603 501(C)(3) 243000 Research Georgia Tech Research Corporation 505 Tenth Street NW Atlanta GA 30318 580603146 501(C)(3) 150000 Research Global Biological Standards Institute 1020 19th Street NW Suite 550 Washington DC 20036 611705421 501(C)(3) 8000 Research H Lee Moffitt Cancer Center 12902 Magnolia Drive Tampa FL 33612 593238636 501(C)(3) 348000 Education Harvard Medical School Holyoke Center Room 600 Cambridge MA 02138 042103580 501(C)(3) 97000 Research Harvard University 25 Shattuck Street Sponsored Prgms Boston MA 02115 042103580 501(C)(3) 120000 Research Henry Ford Health System One Ford Place 5E Detroit MI 48202 381357020 501(C)(3) 200000 Research Howard University 2041 Georgia Avenue NW Washington DC 20060 530204707 501(C)(3) 49994 Education Hudson-Alpha Institute for Biotechnology 601 Genome Way Huntsville AL 35801 432059317 501(C)(3) 28125 Education Indiana University (Indianapolis) PO Box 66057 Indianapolis IN 46266 356001673 501(C)(3) 1477684 Treatment Johns Hopkins University 1101 East 33rd Street Eastern C220 Baltimore MD 21218 520595110 501(C)(3) 2391260 Research Korean Community Svc Ctr of Greater WA Attn Jai Hoon Jung Annandale VA 22003 386005984 501(C)(3) 10000 Education Leland Stanford Jr University PO Box 44253 San Francisco CA 941444253 941156365 501(C)(3) 546989 Screening, Treatment Living Beyond Breast Cancer Attn Jean Sachs CEO Haverford PA 19041 530196932 501(C)(3) 20000 Education, Screening Maasai Wildernes Conservation Fund PO Box 1413 Santa Barbara CA 93102 541943145 501(C)(3) 60000 Research Mary's Ctr for Maternal&Child Care Inc 2333 Ontario Road NW Washington DC 20009 521594116 501(C)(3) 125291 Education Massachusetts General Hospital PO Box 414876 Boston MA 022414876 042697983 501(C)(3) 528910 Education Mayo Clinic Jacksonville Griffin Building Room 170 Jacksonville FL 32224 593337028 501(C)(3) 100000 Research Mayo Clinic Rochester dba Mayo Clinic College of Medicine Rochester MN 559034008 416011702 501(C)(3) 200000 Education Medical College of Wisconsin 1234 Any Street Anywhere TX 75244 390806261 501(C)(3) 150000 Research Medical Univeristy of South Carolina 171 Ashley Avenue Charleston SC 29425 576000722 501(C)(3) 120000 Research Memorial Sloan-Kettering Cancer Ctr 633 3rd Avenue 28th Floor New York NY 10017 131924236 501(C)(3) 160000 Research Metropolitan Chicago Breast Cancer 1645 W Jackson Blvd Ste 450 Chicago IL 606123244 262264895 501(C)(3) 100000 Education, Screening, Treatment MidMichigan Medical Center-Gratiot 300 East Warwick Drive Alma MI 48801 381437919 501(C)(3) 13889 Research Mobile Medical Care Inc 9309 Old Georgetown Road Bethesda MD 208141620 237022588 501(C)(3) 29416 Screening Mount Sinai School of Medicine Sponsored Proj Actg New York NY 100296574 136171197 501(C)(3) 396000 Education Neighborhood Health 6677 Richmond Highway Alexandria VA 22306 541849891 501(C)(3) 139917 Research New York University School of Med General Accounting/Accounts Receiva New York NY 10016 135562308 501(C)(3) 120000 Education North Carolina Central University 1801 Fayetteville Street Durham NC 27707 566000730 501(C)(3) 135000 Research Northwestern University - Chicago 633 Clark Evanston IL 60208 362167817 501(C)(3) 448219 Treatment Nueva Vida Inc 2000 P Street NW Suite 300 Washington DC 20036 541943145 501(C)(3) 64879 Research Obesity Society 8757 Georgia Avenue Silver Spring MD 20910 541438429 501(C)(3) 8000 Research Oregon Health & Science University Sponsored Program Admin Portland OR 97239 752668014 501(C)(3) 909855 Research Partners for Cancer Care and Prevention 10 East Lee Street Unit 1901 Baltimore MD 21202 451605551 501(C)(3) 67500 Research Patient Advocate Foundation 421 Butler Farm Road Hampton VA 23666 830292601 501(C)(3) 25000 Research Prevent Cancer Foundation 1600 Duke Street Alexandria VA 22209 521429544 501(C)(3) 10000 Research Primary Care Coalition-MontgomeryCty Inc 8757 Georgia Avenue 10th Floor Silver Spring MD 20910 521847976 501(C)(3) 250000 Research Prince William Hospital 8700 Sudley Road Manassas VA 20110 541307595 501(C)(3) 93057 Research Princeton University 701 Carnegie Center Princeton NJ 08540 210634501 501(C)(3) 208000 Research Program for Appropriate PO Box 900922 Seattle WA 98109 911157127 501(C)(3) 45646 Research Providence Portland Medical Center 4805 NE Glisan St 5F40 Portland OR 97213 930386906 501(C)(3) 120000 Research Purdue University Sponsored Program Services Chicago IL 606731235 356002041 501(C)(3) 150000 Research Quantum Leap HealthCare Collaborative 3450 California Street San Francisco CA 941181837 204284925 501(C)(3) 10000 Research Reagan Udall Foundation Attn Georges Benjamin MD Washington DC 20001 263727917 501(C)(3) 10000 Research Research Advocacy Network 6505 West Park Boulevard Plano TX 75093 566001393 501(C)(3) 72295 Research Rockefeller University Attn Shawn Davis Ofc of Developme New York NY 10065 131624158 501(C)(3) 150000 Research Roswell Park Alliance Foundation Department of Immunology Buffalo NY 14263 161391608 501(C)(3) 158690 Research Smith Farm Center for Healing & the Arts 1632 U Street NW Washington DC 20009 590624458 501(C)(3) 50000 Research St Joseph Medical Center 2500 Bernville Road Reading PA 196030316 530196617 501(C)(3) 17257 Research Stanford University PO Box 44253 San Francisco CA 941444253 941156365 501(C)(3) 180000 Research Stevens Institute of Technology 1 Castle Point Terrace Hoboken NJ 07030 221487354 501(C)(3) 60000 Research SUNY at Stony Brook Attn Joann DeLucia-Conlon Stony Brook NY 11794 146013200 501(C)(3) 374389 Education, Research Supporting Our Sisters International In 2604 Pinebrook Ave C2 Hyattsville MD 20785 472511778 501(C)(3) 10000 Research Temple University Attn Jeanette West Pastelak Philadelphia PA 19122 231365971 501(C)(3) 60000 Research The Ohio State University College Attn Kathy Milem Columbus OH 43205 316025986 501(C)(3) 258000 Research The Salk Institute Attn Christine Marckese La Jolla CA 920371002 952160097 501(C)(3) 228070 Education, Research The University of Chicago Research Administration Chicago IL 60637 362177139 501(C)(3) 334999 Research The Vanderbilt University PMB 406310 Nashville TN 372406310 620476822 501(C)(3) 48000 Research The Wistar Institute 3601 Spruce Street Philadelphia PA 191044265 236434390 501(C)(3) 150000 Research Trustees of Columbia Univ Sponsored Projects Finance New York NY 10027 135598093 501(C)(3) 150000 Research Trustees of Dartmouth College Office of Sponsored Projects Hanover NH 037551404 020222111 501(C)(3) 120000 Research Tufts University 800 Washington Street Boston MA 02111 042103634 501(C)(3) 242712 Research Tulane University Health Sciences Center 800 E Commerce Harahan LA 70023 720423889 501(C)(3) 120000 Research Univ of Colorado Health Sciences Cent Attn George Johnston Denver CO 802910238 846002597 501(C)(3) 150000 Research Univ of North Carolina at Chapel Hill 104 Airport Drive Suite 2200 CB Chapel Hill NC 275991350 566001393 501(C)(3) 2157806 Research Univ of Texas MD Anderson Cancer Center Grants Contracts Houston TX 772104390 746001118 501(C)(3) 774111 Research University Miami School of Medicine Attn Maria A Garcia Atlanta GA 303845803 590624458 501(C)(3) 120000 Research University of Alabama at Birmingham 1530 3rd Avenue South Birmingham AL 352940111 636005396 501(C)(3) 408000 Education, Screening, Treatment University of California-San Francisco 1600 Divisadero St Box 1710 San Francisco CA 94115 946036493 501(C)(3) 764159 Research University of California-Berkeley 2195 Hearst Avenue Room 130 Berkeley CA 947201103 946002123 501(C)(3) 243000 Research University of California-Davis Cashiers Office West Sacramento CA 957989062 946036494 501(C)(3) 59983 Research University of California-Los Angeles UCLA Remittance Center Los Angeles CA 900246503 956006143 501(C)(3) 390000 Research University of California-San Diego UCSD Cashiers Office La Jolla CA 92093 956006144 501(C)(3) 228000 Education, Treatment University of Cincinnati 51 Goodman Dr Univ Hall Suite 5 Cincinnati OH 452210222 316000989 501(C)(3) 120000 Screening University of Colorado Denver 13001 E 17th Place Aurora CO 800452571 846002597 501(C)(3) 75975 Research University of Delaware 30 Lovett Aenue Newark DE 19716 516000279 501(C)(3) 150000 Education University of Illinois at Chicago 809 S Marshfield Avenue MC551 Chicago IL 606081264 376000511 501(C)(3) 104059 EDUCATION University of Illinois-Urbana-Champaign Grants Contracts-Post Award Springfield IL 627084610 376000511 501(C)(3) 60000 SCREENING University of Kansas Medical Center ATTN TIM SISKEY KANSAS CITY KS 66 Kansas City KS 66160 481108830 501(C)(3) 583275 EDUCATION University of Kentucky Research Fndn Markey Cancer Center Lexington KY 405260001 616033693 501(C)(3) 75948 EDUCATION University of Massachusetts Amherst Goodell Bldg Room 405 Amherst MA 010033210 043167352 501(C)(3) 149944 EDUCATION University of Miami School of Medicine Center for Cancer Prevention and Ge Miami FL 33136 590624458 501(C)(3) 60000 RESEARCH University of Michigan Alexandra Thebaud Ann Arbor MI 481091274 386006309 501(C)(3) 255000 EDUCATION University of Minnesota McNamara Alumni Center Minneapolis MN 554552070 416007513 501(C)(3) 180000 RESEARCH University of Pennsylvania Office of Research Services Philadelphia PA 191046205 231352685 501(C)(3) 819727 EDUCATION University of Pittsburgh 350 Thackeray Hall Pittsburgh PA 15260 250965591 501(C)(3) 773574 EDUCATION University of South CarolinaThe 1600 Hampton Street Suite 404H Columbia SC 29208 576001153 501(C)(3) 135000 RESEARCH University of Southern California Attn Robert Osuna Los Angeles CA 900898001 951642394 501(C)(3) 818086 RESEARCH University of Texas at Health Science Ce Elizabeth Frantz Houston TX 77030 741587488 501(C)(3) 259916 EDUCATION, SCREENING University of Utah 201 South Presidents Circle Room Salt Lake City UT 841129020 876000525 501(C)(3) 296000 RESEARCH University of Virginia at School of Medi PO Box 400195 Charlottesville VA 229044195 546001796 501(C)(3) 150000 RESEARCH University of Washington Attn Tami Sadusky Seattle WA 98105 916001537 501(C)(3) 502837 EDUCATION University of Wisconsin - Madison Research Sponsored Programs Madison WI 537151218 396006492 501(C)(3) 179383 EDUCATION, SCREENING UT HSC - San Antonio Office of Sponsored Programs San Antonio TX 772293900 741586031 501(C)(3) 150000 RESEARCH UT Southwestern Medical Center UT Southwestern Grants Mgmt Dallas TX 752841753 746000203 501(C)(3) 210000 RESEARCH UTMD Anderson Cancer Ctr 1515 Holcombe Boulevard Unit 1644 Houston TX 770304009 746001118 501(C)(3) 364479 EDUCATION, TREATMENT Vanderbilt University Medical Center 1161 21st Avenue South Nashville TN 372325545 620476822 501(C)(3) 1242169 EDUCATION, RESEARCH Vermont Cancer Ctr UVM College of Med Attn Jennifer Gagnon Burlington VT 05405 030179440 501(C)(3) 150000 RESEARCH Vietnamese Resettlement Association Inc Attn Kim O Cook Falls Church VA 22044 541512549 501(C)(3) 279182 RESEARCH Virginia Commonwealth University Attn Mark Roberts Richmond VA 232843038 546001758 501(C)(3) 25204 RESEARCH Washington Univ at St Louis 700 Rosedale Ave Campus Box 1034 St Louis MO 63112 430653611 501(C)(3) 1059427 RESEARCH Wayne State University Sponsored Program Admin Detroit MI 48201 366028429 501(C)(3) 143999 EDUCATION Weill Medical College of Cornell Univ 1300 York Avenue New York NY 10061 131623978 501(C)(3) 60000 EDUCATION Whitehead Inst for Biomedical Research 9 Cambridge Center Cambridge MA 021421479 061043412 501(C)(3) 48000 EDUCATION Whitman-Walker Clinic 1701 14th Street NW Washington DC 20009 521122122 501(C)(3) 194136 RESEARCH Yale University 2 Whitney Avenue New Haven CT 06510 060646973 501(C)(3) 200000 RESEARCH Young Survival Coalition Lori Atkinson New York NY 10006 134057685 501(C)(3) 10000 RESEARCH 142 PROCEDURES FOR MONITORING THE USE OF GRANTS SCHEDULE I PART I LINE 2 SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED THROUGHOUT THE GRANT TERM BY A PH.D.-LEVEL RESEARCH GRANT MANAGER. FOR EDUCATION, SCREENING, AND TREATMENT GRANTS, PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED OR SUPERVISED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANTS MANAGERS. EACH YEAR OF THE GRANT TERM, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. X X X X X X true false false false false false false false false Robert Green Chief Financial Officer 279292 5092 8644 0 2165 0 295193 0 0 0 Adam Vanek BEG 417 Gen. Counsel & Asst Corp Secy 164539 1624 0 0 23926 0 190089 0 0 0 Ellen Willmott INTERIM CEO (END 10/17) 341849 34725 3882 15973 0 10866 0 407295 0 0 0 Christina Alford SVP, Development 280188 2100 14385 0 4930 0 301603 0 0 0 Victoria Wolodzko VP Research and Com. Health Pr 183156 2370 10914 0 10693 0 207133 0 0 0 Lori Maris SVP, Affiliate Network 167873 2559 7370 0 11415 0 189217 0 0 0 Eric Montgomery VP, I.T. 192148 1995 9526 0 37127 0 240796 0 0 0 Catherine Olivieri VP, Human Resources 215234 2802 13834 0 38380 0 270250 0 0 0 Andrea Rader Sr Dir, Com. (End 04/18) 169826 2943 10481 0 17968 0 201218 0 0 0 Ria Williams Controller 170058 2001 8369 0 34131 0 214559 0 0 0 Subhendu Rath Sr Dir, IT Enterprise Systems 163037 1762 9912 0 18785 0 193496 0 0 0 Vanessa Hewitt Sr Dir, Internal Audit 156643 1795 9856 0 20704 0 188998 0 0 0 Kimberly Sabelko Sr Dir, Scientific Strategy 152257 2498 9132 0 21149 0 185036 0 0 0 Dr Judith Salerno Former President & CEO 0 271623 0 0 0 0 271623 0 0 0 FORM 990, SCHEDULE J, PART I, LINE 1A SUPPLEMENTAL COMPENSATION INFORMATION EXCEPT AS MAY BE APPROVED IN ADVANCE FOR MEDICAL ACCOMMODATION, FIRST CLASS AND BUSINESS CLASS FARES FOR DOMESTIC TRAVEL, CANADA, THE CARIBBEAN, CENTRAL AMERICA, AND MEXICO ARE NOT REIMBURSABLE. HOWEVER, PERSONAL FREQUENT FLIER MILEAGE AND/OR COUPONS MAY BE USED FOR NO-COST UPGRADES. IN THE EVENT OF INTERNATIONAL TRAVEL WITH FLIGHT TIMES OF SIX HOURS OR MORE, AND PRE-APPROVAL BUSINESS OR FIRST CLASS TRAVEL MAY BE PERMITTED IF THERE IS A MEDICAL ACCOMODATION OR BUSINESS PURPOSE. WHENEVER POSSIBLE, DISCOUNTED FIRST CLASS AND UPGRADES ARE USED TO MINIMIZE COST. FORM 990, SCHEDULE J, PART I, LINE 4A Dr. Judith Salerno received a severance payment of $271,623. X 3800 14577 FMV X Tablecloths & Flowers 16 3568 FMV X Exercise Supplies 20 1035 FMV X Golf Equip Inventory 8559 207017 FMV false true false VOLUNTEERS FORM 990, PART I, LINE 6 VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE SUSAN G. KOMEN 3 DAY SERIES. FORM 990, PART III - PROGRAM SERVICE ACCOMPLISHMENTS SUSAN G. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE THE U.S. GOVERNMENT WHILE PROVIDING REAL TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS FUNDED MORE THAN $988 MILLION IN BREAST CANCER RESEARCH AND PROVIDED OVER $2.2 BILLION IN FUNDING FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, HEALTH SYSTEMS IMPROVEMENT, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, AND DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS AND TECHNOLOGIES THAT WILL REDUCE THE NUMBER OF BREAST CANCER DEATHS IN THE U.S. BY 50 PERCENT BY 2026. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 60 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS, EMPHASIZING URGENCY AND PATIENT IMPACT. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY18, KOMEN AWARDED MORE THAN 60 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, COLLABORATIONS AND TRAINING IN THE UNITED STATES AND OTHER COUNTRIES, INCLUDING AUSTRALIA, CANADA, FRANCE, AND IRELAND. WE CONSIDER IT OUR RESPONSIBILITY TO ENSURE THE CONTINUITY OF BREAST CANCER RESEARCH FOR THE FUTURE. WITH FEDERAL RESEARCH BUDGETS TIGHTENING, THE PUBLIC CANNOT AFFORD TO LOSE PROMISING YOUNG INVESTIGATORS DUE TO A LACK OF FUNDING OPPORTUNITIES. TO THAT END, KOMEN AWARDED CAREER CATALYST RESEARCH GRANTS (WITH A COMPETITIVE RENEWAL OPTION) TO SUPPORT YOUNG INVESTIGATORS IN BREAST CANCER RESEARCH ADDRESSING TWO OF THE GREATEST CHALLENGES FACING BREAST CANCER PATIENTS -DRUG-RESISTANT BREAST CANCERS AND NEW APPROACHES TO COMBAT METASTATIC BREAST CANCER. KOMEN ALSO OFFERED LEADERSHIP GRANTS AND A PHASE II COMPETITIVE RENEWAL OF THE INFLAMMATORY BREAST CANCER RESEARCH INNOVATOR GRANTS. EACH MECHANISM IS FURTHER DESCRIBED BELOW: CAREER CATALYST RESEARCH GRANTS (CCR): CCR GRANTS PROVIDE UNIQUE OPPORTUNITIES FOR SCIENTISTS WHO HAVE HELD FACULTY POSITIONS FOR NO MORE THAN 5 YEARS AT THE TIME OF FULL APPLICATION TO ACHIEVE RESEARCH INDEPENDENCE. THE GOAL OF THE FY18 CCR GRANTS IS TO SUPPORT OUTSTANDING TRANSLATIONAL RESEARCH FOCUSED ON THOSE BREAST CANCERS THAT DO NOT CURRENTLY RESPOND WELL TO STANDARD THERAPIES INCLUDING TRIPLE NEGATIVE BREAST CANCER (TNBC), ER+ BREAST CANCER WITH ACQUIRED RESISTANCE, AND METASTATIC BREAST CANCER OF ALL SUB-TYPES. CCR GRANTS SUPPORT WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS AND TECHNOLOGIES THAT WILL REDUCE THE NUMBER OF BREAST CANCER DEATHS IN THE U.S. BY 50 PERCENT BY 2026. CAREER CATALYST RESEARCH GRANTS-COMPETING RENEWALS (CCR-CR): CCR-CR GRANTS WERE DESIGNED TO ADDRESS THE INTENSE COMPETITION AND LACK OF FUNDING THAT MAY CAUSE TALENTED YOUNG SCIENTISTS TO LEAVE THE FIELD. CCR-CR GRANTS ARE INTENDED TO PROVIDE CONTINUED SUPPORT TO EARLY CAREER BREAST CANCER RESEARCHERS AND CLINICIAN-SCIENTISTS WHO HAVE HAD PRIOR KOMEN CCR GRANT SUPPORT, BUT HAVE NOT YET SECURED SUPPORT AS A PRINCIPAL INVESTIGATOR THROUGH A NATIONAL INSTITUTES OF HEALTH R01 AWARD OR OTHER INDEPENDENT AWARD SIMILAR IN SCOPE. IT IS EXPECTED THAT AWARDEES WILL LEVERAGE THE CCR-CR GRANT TO SUCCESSFULLY COMPETE FOR ADDITIONAL INDEPENDENT RESEARCH FUNDING IN BREAST CANCER, AND THUS REMAIN IN THE FIELD. INFLAMMATORY BREAST CANCER (IBC) RESEARCH INNOVATOR GRANTS: GENEROUSLY SUPPORTED BY THE MILBURN FOUNDATION AND THE INFLAMMATORY BREAST CANCER RESEARCH FOUNDATION, THESE INNOVATOR GRANTS ARE INTENDED TO SPUR IDEAS THAT WILL INCREASE THE UNDERSTANDING OF HOW IBC CAN BE BETTER DIAGNOSED AND HOW BIOLOGY DRIVES ITS PROGRESSION, THEREBY LEADING TO IMPROVED PROGNOSIS AND MORE EFFECTIVE TREATMENTS FOR THOSE WITH THIS AGGRESSIVE DISEASE. THIS PROGRAM CONSISTED OF TWO STAGES. IN THE FIRST STAGE, ONE YEAR OF FUNDING WAS AWARDED TO ALLOW INVESTIGATORS TO ESTABLISH THE FOUNDATION OF A ROBUST AND INNOVATIVE IBC RESEARCH PROJECT. IN THE SECOND STAGE, AWARDEES COMPETED FOR ADDITIONAL FUNDING TO BUILD ON THEIR ORIGINAL PROJECT AND ONE GRANT WAS FUNDED. LEADERSHIP GRANTS: LEADERSHIP GRANTS PROVIDE SUPPORT FOR HYPOTHESIS-DRIVEN RESEARCH PROJECTS CONDUCTED BY THE DISTINGUISHED BREAST CANCER RESEARCHERS AND CLINICIANS WHO SERVE AS KOMEN'S SCIENTIFIC ADVISORS AND SEEK TO DISCOVER AND DELIVER THE CURES FOR BREAST CANCER. OPPORTUNITY GRANTS / STRATEGIC PARTNERSHIP AND PROGRAM GRANTS (OG/SPP): OG AND SPP GRANTS SUPPORT SPECIAL RESEARCH PROJECTS, PROGRAMS, AND COLLABORATIONS THAT LEVERAGE RESEARCH AND COMMUNITY RESOURCES TO FACILITATE THE DEVELOPMENT OF THE INFRASTRUCTURE, TOOLS, AND OTHER MEANS TO ACCELERATE THE TRANSLATION OF SCIENTIFIC DISCOVERIES FROM BENCH TO BEDSIDE TO CURBSIDE. FUNDING FROM ORGANIZATIONS LIKE KOMEN AND ITS SUPPORTERS HAS PROVEN CRITICAL FOR ALL THESE ACTIVITIES, ESPECIALLY AT A TIME OF DIMINISHING FEDERAL FUNDING FOR CANCER RESEARCH AND FOR CLINICAL TRIALS. KOMEN'S RESEARCH INVESTMENT THROUGH THESE GRANT MECHANISMS SUPPORTS PROJECTS THAT AIM TO, AMONG OTHER THINGS: (A) DEVELOP TARGETED THERAPIES;(B) OVERCOME AGGRESSIVE TYPES OF BREAST CANCER AND METASTASIS; (C) OVERCOME TREATMENT RESISTANCE; AND (D) UNDERSTAND AND ADDRESS DISPARITIES IN OUTCOMES. EXAMPLES OF RESEARCH GRANTS AWARDED IN FY18 INCLUDE: A) TARGETED THERAPIES FOR TRIPLE-NEGATIVE BREAST CANCER: DR. SOHRAB SHAH FROM MEMORIAL SLOAN-KETTERING CANCER CENTER WAS AWARDED A LEADERSHIP GRANT TO COMBINE AND ANALYZE GENOMIC AND CLINICAL DATA FROM APPROXIMATELY 300 PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER (TNBC) TO STUDY HOW MUTATIONS IN THE DNA OF TNBC CELLS CAN BE USED TO DESIGN BETTER TREATMENT APPROACHES. USING STATE-OF-THE-ART DNA SEQUENCING TECHNOLOGIES, DR. SHAH WILL MEASURE THE DNA OF INDIVIDUAL CANCER CELLS TO CREATE AN ULTRA-DETAILED PICTURE OF HOW TNBC CHANGES OVER TIME. THESE DETAILED VIEWS WILL REVEAL PREVIOUSLY UNSEEN PATTERNS OF DNA MUTATIONS IN TNBC, WHICH WILL BE USED TO STRATIFY PATIENTS INTO BIOLOGICALLY DISTINCT SUBGROUPS WITH DIFFERENT SENSITIVITIES TO CHEMOTHERAPY. THE DATA GENERATED FROM HIS PROJECT WILL BE USED TO HELP STRATIFY PATIENTS ACCORDING TO TREATMENT RESPONSE AND OUTCOMES, POTENTIALLY DIRECTING PATIENTS TO MORE TARGETED THERAPIES, WHICH ARE CURRENTLY LACKING FOR TNBC. B) OVERCOME AGGRESSIVE TYPES OF BREAST CANCER AND METASTASIS: DR. XIA LIU FROM NORTHWESTERN UNIVERSITY'S FEINBERG SCHOOL OF MEDICINE WAS AWARDED A CCR GRANT TO TEST WHETHER TWO NATURAL COMPOUNDS - HYPERFORIN AND BOSWELLIA - CAN BE USED ALONE OR IN COMBINATION WITH ANOTHER IMMUNOTHERAPY, A CHECKPOINT INHIBITOR CALLED ANTI PD-1 ANTIBODY, TO PREVENT THE ABILITY OF NEUTROPHILS TO PROMOTE METASTASIS. HYPERFORIN IS A PLANT-DERIVED ANTIBIOTIC FROM ST. JOHN'S WORT AND BOSWELLIA IS A PLANT THAT PRODUCES INDIAN FRANKINCENSE. DR. LIU WILL ALSO CONDUCT STUDIES TO UNCOVER HOW NEUTROPHILS INTERACT WITH TUMOR CELLS IN THE BLOOD TO PROMOTE METASTASIS. SHE WILL IDENTIFY THE MOLECULES THAT FACILITATE THIS INTERACTION AND DETERMINE WHETHER THESE MOLECULES CAN SERVE AS BIOMARKERS TO PREDICT METASTASIS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER, HELPING TO GUIDE TREATMENT STRATEGIES. C) OVERCOME TREATMENT RESISTANCE: DR. SVASTI HARICHARAN AT BAYLOR COLLEGE OF MEDICINE WAS AWARDED A CCR GRANT TO STUDY ENDOCRINE THERAPY RESISTANCE IN ER+ BREAST CANCER. PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER ARE TREATED WITH ENDOCRINE THERAPY, BUT ABOUT 1/3 OF ER+ PATIENTS DO NOT RESPOND TO THIS TREATMENT AND EVENTUALLY DIE OF THE DISEASE. DR. HARICHARAN HAS DISCOVERED THAT TUMORS WITH DEFECTS IN THEIR ABILITY TO REPAIR MISMATCHES IN DNA ARE RESISTANT TO ENDOCRINE THERAPIES, AND UP TO 30% OF ENDOCRINE TREATMENT RESISTANT TUMORS SHOW THIS DEFECT. DR. HARICHARAN WILL MOVE THIS DISCOVERY INTO THE CLINIC BY 1) DEVELOPING A SIMPLE DIAGNOSTIC TEST SO THAT CLINICIANS CAN IDENTIFY TUMORS WITH DEFECTIVE MISMATCH REPAIR AND 2) IDENTIFYING EXISTING FDA-APPROVED DRUGS THAT CAN TREAT THESE TUMORS MORE EFFECTIVELY THAN ENDOCRINE TREATMENT. THIS STUDY WILL HELP IDENTIFY WOMEN LIKELY TO DEVELOP DRUG RESISTANCE EARLY IN THE TIMELINE OF THEIR CANCER TREATMENT, PROVIDING DOCTORS A CRUCIAL OPPORTUNITY TO PERSONALIZE THERAPY TO EACH PATIENT. D) UNDERSTAND AND ADDRESS DISPARITIES IN OUTCOMES: RACHEL FREEDMAN, M.D., M.P.H., OF DANA-FARBER CANCER INSTITUTE WILL INVESTIGATE WAYS TO IMPROVE SURVIVAL FOR BREAST CANCER PATIENTS THAT ARE 70 YEARS OF AGE OR OLDER. OLDER PATIENTS OFTEN FACE WORSE OUTCOMES WHEN COMPARED TO THEIR YOUNGER COUNTERPARTS. THE GOAL OF THIS STUDY IS TO IDENTIFY TAILORED TREATMENT METHODS THAT WILL IMPROVE SURVIVAL FOR THIS POPULATION OF PATIENTS. KOMEN SCHOLAR JULIE PALMER, SC.D., OF BOSTON UNIVERSITY WILL DEVELOP A RISK PREDICTION TOOL THAT WILL CONSIDER THE DIFFERENT RISK FACTORS FOR ER+ AND ER- BREAST CANCER, ALONG WITH THE DIFFERING AGE INCIDENCE PATTERNS IN AFRICAN AMERICAN WOMEN. THIS TOOL WILL HELP IDENTIFY AFRICAN AMERICAN WOMEN WHO WOULD BENEFIT FROM EARLIER AND MORE FREQUENT SCREENING OR ALTERNATIVE MODES OF SCREENING. EDUCATION AND PATIENT SUPPORT: KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE "ABOUT BREAST CANCER" SECTION OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER/BRIGHAM AND WOMEN'S CANCER CENTER STAFF, RECEIVED MORE THAN 5.6 MILLION PAGE VIEWS DURING FY18. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACTSHEETS, C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS, AND D) TOOLKITS FOR BREAST CANCER OUTREACH AND EDUCATION FOR HISPANIC/LATINO IN ENGLISH AND SPANISH AND FOR BLACK AND AFRICAN-AMERICAN COMMUNITIES. THE SUSAN G. KOMEN "1-877 GO KOMEN" (1-877-465-6636) BREAST CARE HELPLINE OFFERS BREAST CANCER EDUCATION, PSYCHOSOCIAL SUPPORT, AND INFORMATION ABOUT COMMUNITY RESOURCES FOR PATIENTS, FAMILIES, AND FRIENDS. IN FY18, KOMEN ADDED A CLINICAL TRIAL INFORMATION HELPLINE TO PROVIDE INFORMATION, RESOURCES, COACHING AND SUPPORT RELATED TO BREAST CANCER CLINICAL TRIALS. THE HELPLINE OPERATES FROM 9 A.M. - 10 P.M. E.T. THE SERVICE IS OFFERED IN ENGLISH, SPANISH, AND TAGALOG. DURING FY18, THE KOMEN BREAST CANCER HELPLINE RESPONDED TO MORE THAN 13,000 CALLS AND EMAILS. IN ADDITION, IN FY18 KOMEN SUPPORTED TWO NONPROFIT ADVOCACY ORGANIZATIONS TO PRESENT PATIENT-FOCUSED, EDUCATIONAL CONFERENCES DEDICATED TO THE CRITICAL ISSUES FACING BREAST CANCER PATIENTS AND THEIR FAMILIES. KOMEN FUNDS THE LIVING BEYOND BREAST CANCER'S (LBBC) CONFERENCE FOR WOMEN LIVING WITH METASTATIC BREAST CANCER IN THE WASHINGTON, D.C. REGION. THE CONFERENCE BRINGS PEOPLE WITH METASTATIC BREAST CANCER, CAREGIVERS, HEALTHCARE PROFESSIONALS, HEALTHCARE ORGANIZATIONS, SUPPORT ORGANIZATIONS AND OTHERS, WHO PARTICIPATE IN THE CARE OF PATIENTS WITH METASTATIC BREAST CANCER, TO DISCUSS SCIENTIFIC BREAKTHROUGHS, ONGOING CLINICAL TRIALS, QUALITY OF LIFE, AND INTEGRATIVE MEDICINE. THE CONFERENCE IS DESIGNED TO FILL THE NEEDS OF THE METASTATIC BREAST CANCER COMMUNITY AND SEEKS TO STRENGTHEN METASTATIC BREAST CANCER VOICES IN THE NATIONAL CAPITAL REGION BY CREATING OPPORTUNITIES FOR LEARNING, ENGAGEMENT AND ACTION. BREAST CANCER IS THE MOST COMMON CANCER IN WOMEN, WORLDWIDE, AND THE NUMBER OF CASES IS INCREASING IN NEARLY EVERY COUNTRY. THE NUMBER OF NEW BREAST CANCER CASES HAS MORE THAN DOUBLED AROUND THE WORLD IN THE LAST THREE DECADES, WITH HIGHEST INCREASES OBSERVED IN LOW- AND MIDDLE-INCOME COUNTRIES. BREAST CANCER IS ALSO THE LEADING CAUSE OF CANCER DEATH IN THESE COUNTRIES, WITH OVER 500,000 DEATHS IN 2012. THESE TRENDS ARE CONCERNING, WHICH IS WHY KOMEN WORKS TIRELESSLY TO PROVIDE SUPPORT TO BREAST HEALTH PROGRAMS WORLDWIDE. IT TAKES COLLABORATION AND STRONG PARTNERSHIPS TO MAKE A GLOBAL IMPACT. KOMEN STRIVES TO SERVE AS A "BRIDGE" - COLLABORATING WITH INTERNATIONAL NONPROFITS, CORPORATIONS, AND MINISTRIES OF HEALTH TO BRING TOGETHER PEOPLE AND ORGANIZATIONS TO DEVELOP PROGRAMS THAT ARE TAILORED TO THE SPECIFIC NEEDS OF THE COMMUNITY AND SENSITIVE TO CULTURAL DIFFERENCES. IN FY18, KOMEN'S GLOBAL PROGRAM AWARDED TEN GRANTS TO SUPPORT EDUCATION PROGRAMMING FOR PATIENTS AND FOR HEALTH PROFESSIONALS AND TO REDUCE BARRIERS TO BREAST CANCER CARE IN CHINA, COLOMBIA, MEXICO, PANAMA, AND ZAMBIA. IN ZAMBIA, SUSAN G. KOMEN PARTNERED WITH CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA (CIDRZ) TO CONVENE THE CANCER PREVENTION ALLIANCE OF ZAMBIA (CAPRAZ). THIS COUNTRY-WIDE ALLIANCE OF CANCER ADVOCACY GROUPS WILL WORK TO INTENSIFY BREAST AND CERVICAL CANCER EDUCATION CAMPAIGNS IN COMMUNITIES TO DISPEL MYTHS AND MISCONCEPTIONS; ENSURE THE BREAST AND CERVICAL CANCER HEALTH PROMOTION MESSAGES ARE EVIDENCE-BASED AND CONTEXTUALLY RELEVANT; AND COORDINATE AND PROVIDE TECHNICAL SUPPORT FOR EDUCATION ACTIVITIES OF MEMBER GROUPS. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE VOICE FOR THE MORE THAN 3.5 MILLION BREAST CANCER SURVIVORS AND THOSE WHO LOVE THEM. KOMEN WORKS TO ENSURE THAT THE FIGHT AGAINST BREAST CANCER IS A PRIORITY AMONG POLICYMAKERS IN WASHINGTON, D.C., AND EVERY STATE CAPITOL ACROSS THE COUNTRY. EVERY TWO YEARS, THROUGH A TRANSPARENT, BROAD-BASED AND INTENSIVE VETTING AND SELECTION PROCESS, KOMEN WORKS TO IDENTIFY THE POLICY ISSUES WITH THE GREATEST POTENTIAL MISSION IMPACT. THIS PROCESS INCLUDES COLLECTING FEEDBACK FROM KOMEN HEADQUARTERS' LEADERSHIP, POLICY STAFF, AND SUBJECT MATTER EXPERTS; KOMEN AFFILIATES FROM ACROSS THE COUNTRY; ADVISORY GROUPS INCLUDING ADVOCATES IN SCIENCE (AIS) AND KOMEN SCHOLARS; AND OTHER STAKEHOLDERS WITH A VESTED INTEREST IN BREAST CANCER-RELATED ISSUES. THE SELECTED ISSUES ARE THE BASIS FOR KOMEN'S STATE AND FEDERAL ADVOCACY. KOMEN'S 2017-2018 ADVOCACY PRIORITIES INCLUDED: SUPPORTING EXPANDED FEDERAL FUNDING FOR BREAST CANCER RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE DEPARTMENT OF DEFENSE (DOD); SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC MAMMOGRAPHY; AND EVALUATING STATE AND FEDERAL POLICIES TO INCREASE PUBLIC ACCESS TO INFORMATION ABOUT AND PARTICIPATION IN CLINICAL TRIALS FOR ALL PATIENT POPULATIONS. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR 2017-2018 ADVOCACY PRIORITIES, KOMEN CONTINUED OUR EFFORTS TO ENSURE EVERY BREAST CANCER PATIENT AND SURVIVOR HAS ACCESS TO AFFORDABLE, QUALITY HEALTH INSURANCE AND CARE. KOMEN ALSO ENGAGED ON ISSUES RELATED TO BREAST DENSITY, COMPASSIONATE USE, GENETIC TESTING, HEALTH DISPARITIES, LYMPHEDEMA, METASTATIC BREAST CANCER, PALLIATIVE CARE AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES AND ADDITIONAL POLICY AREAS TO ACHIEVE KOMEN'S BOLD GOAL. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK. SCREENING AND PATIENT NAVIGATION GETTING REGULAR SCREENING TESTS, ALONG WITH EFFECTIVE AND QUALITY TREATMENT IF DIAGNOSED, LOWERS THE RISK OF DYING FROM BREAST CANCER. SCREENING TESTS CAN FIND BREAST CANCER EARLY, WHEN CHANCES FOR SURVIVAL ARE HIGHEST. PATIENT NAVIGATION IS A PROCESS BY WHICH AN INDIVIDUAL - A PATIENT NAVIGATOR - GUIDES PATIENTS THROUGH AND AROUND BARRIERS IN THE COMPLEX CANCER CARE SYSTEM. EVIDENCE SHOWS NAVIGATION IMPROVES ADHERENCE TO SCREENING RECOMMENDATIONS, AND THUS IMPROVES OVERALL OUTCOMES. KOMEN SUPPORTS FREE AND LOW-COST SCREENING PROGRAMS IN UNDERSERVED COMMUNITIES THAT HELP NAVIGATE PEOPLE TO QUALITY CARE, AND/OR PROVIDE COVERAGE FOR SCREENING SERVICES TO PEOPLE WITHOUT HEALTH INSURANCE, OR THOSE WITH HIGH CO-PAYS AND DEDUCTIBLES THAT MAKE SCREENING TOO COSTLY. IN FY18, KOMEN AWARDED ONE SCREENING COMMUNITY GRANT TO THE AMERICAN ASSOCIATION ON HEALTH AND DISABILITY. THE PROJECT FOCUSES ON WOMEN WITH DISABILITIES IN WASHINGTON D.C., PARTICULARLY BLACK AND AFRICAN-AMERICAN WOMEN, WITH THE ULTIMATE GOAL OF INCREASING BREAST CANCER CARE UTILIZATION THROUGH DECREASING BARRIERS TO ACCESS CARE, LEADING TO REDUCED MORTALITY. THROUGH ITS GLOBAL PROGRAM, KOMEN AWARDED TEN GRANTS TO COMMUNITY ORGANIZATIONS IN SUPPORT OF SCREENING AND PATIENT NAVIGATION PROGRAMS IN MEXICO, PANAMA, CHINA, COLUMBIA, AND ZAMBIA. TREATMENT AND PATIENT NAVIGATION BARRIERS TO QUALITY CARE ARE OFTEN ASSOCIATED WITH POOR BREAST CANCER OUTCOMES AND RESULTANT CANCER DISPARITIES AMONG SPECIFIC POPULATION GROUPS. ACCORDING TO QUALITATIVE DATA COLLECTED FROM ACROSS KOMEN'S AFFILIATE NETWORK, THE MOST COMMON BARRIERS TO QUALITY CARE IN THE UNITED STATES INCLUDE: (1) AVAILABILITY OF LOCAL SERVICES; (2) BREAST CANCER EDUCATION; (3) CULTURAL/LANGUAGE; (4) FEAR; (5) FINANCIAL; (6) INSURANCE; (7) TRANSPORTATION. PATIENT NAVIGATION IS A PROCESS BY WHICH AN INDIVIDUAL - A PATIENT NAVIGATOR - GUIDES PATIENTS THROUGH AND AROUND BARRIERS IN THE COMPLEX CANCER CARE SYSTEM TO ENSURE TIMELY DIAGNOSIS AND TREATMENT. EVIDENCE SHOWS PATIENT NAVIGATION IMPROVES ADHERENCE TO TREATMENT RECOMMENDATIONS, RESULTING IN IMPROVED OUTCOMES. IN FY18, KOMEN FUNDED THREE NONPROFIT ORGANIZATIONS IN SUPPORT OF PROGRAMS TO REDUCE STRUCTURAL, PERSONAL, SOCIOCULTURAL, AND FINANCIAL BARRIERS TO CARE, AND PROVIDE PATIENT NAVIGATION SERVICES FOR UNDERSERVED COMMUNITIES IN THE WASHINGTON, D.C. METRO AREA, SPECIFICALLY WARDS 2, 5, 7, AND 8, AND ALEXANDRIA CITY, VA. THROUGH ITS GLOBAL PROGRAM IN FY18, KOMEN AWARDED TEN GRANTS TO COMMUNITY ORGANIZATIONS IN SUPPORT OF TREATMENT AND PATIENT NAVIGATION PROGRAMS AND TO REDUCE BARRIERS TO BREAST CANCER CARE IN CHINA, COLOMBIA, MEXICO, PANAMA, AND ZAMBIA. FOR EXAMPLE, KOMEN SUPPORTED CASITA DE MAUSI TO PROVIDE LODGING, TRANSPORTATION, AND MEALS FOR BREAST CANCER PATIENTS FROM RURAL COMMUNITIES IN PANAMA, FACILITATING THEIR ACCESS TO BREAST CANCER SERVICES. KOMEN ALSO SUPPORTED ALIANZA MEXICANA POR EL CNCER IN MEXICO TO IMPROVE THE CURRENT OUTLOOK OF BREAST CANCER IN MEXICO THROUGH THE EARLY DETECTION, DIAGNOSIS, AND TREATMENT OF BREAST CANCER; IMPROVING CLINICAL CARE OF PATIENTS; ENCOURAGING MULTIDISCIPLINARY RESEARCH OF BREAST CANCER IN MEXICO; EXPANDING THE EDUCATION OF THE PUBLIC, PATIENTS, AND HEALTH PROFESSIONALS; AND GUARANTEEING THE REPLICABILITY OF THE PROGRAMS WE FOSTER. KOMEN'S TREATMENT ASSISTANCE PROGRAM, ADMINISTERED BY CANCERCARE, AIMS TO HELP WOMEN AND MEN IN BREAST CANCER TREATMENT WHO ARE FACING FINANCIAL CHALLENGES BY PROVIDING LIMITED FINANCIAL ASSISTANCE, EDUCATION, AND SUPPORT SERVICES. FINANCIAL ASSISTANCE IS GRANTED TO UNDERSERVED, UNDERINSURED OR UNINSURED WOMEN AND MEN ACROSS THE COUNTRY UNDERGOING BREAST CANCER TREATMENT WHO MEET PRE-DETERMINED ELIGIBILITY CRITERIA. THIS PROGRAM PROVIDES FINANCIAL ASSISTANCE FOR TREATMENT-RELATED COSTS, INCLUDING TRANSPORTATION TO AND FROM TREATMENT, CHILD/ELDER CARE, HOME CARE, ORAL PAIN/ANTI-NAUSEA MEDICATIONS, ORAL CHEMOTHERAPY/HORMONE THERAPY, LYMPHEDEMA CARE/SUPPLIES, PALLIATIVE CARE, AND DURABLE MEDICAL EQUIPMENT. WE SERVED MORE THAN 3200 PEOPLE THROUGH THIS PROGRAM IN FY18. EXECUTIVE COMMITTEE FORM 990, PART VI, LINE 1A THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES. DESCRIBE THE PROCESS USED BY MANAGEMENT &/OR GOVERNING BODY TO REVIEW 990 FORM 990, PART VI, LINE 11B MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING. DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICTS OF INTEREST FORM 990, PART VI, LINE 12C KOMEN PRODUCES AN ANNUAL SURVEY REQUIRING ALL EMPLOYEES, BOARD MEMBERS, COMMITTEE MEMBERS, AND ADVISORY BOARD MEMBERS TO DISCLOSE ANY POTENTIAL OR ACTUAL CONFLICTS OF INTEREST THEY MAY HAVE. ANY REPORTED POTENTIAL OR ACTUAL CONFLICTS ARE THEN REVIEWED BY SENIOR MANAGEMENT AND THE AUDIT COMMITTEE, WHEREUPON APPROPRIATE MEASURES ARE TAKEN. ALL EMPLOYEES, BOARD MEMBERS, COMMITTEE MEMBERS AND ADVISORY BOARD MEMBERS ARE REQUIRED TO UPDATE THEIR RESPECTIVE CONFLICT OF INTEREST DISCLOSURES AS NECESSARY DURING THE YEAR. OFFICES & POSITION FOR WHICH PROCESS WAS USED, & YEAR PROCESS WAS BEGUN FORM 990, PART VI, LINES 15A AND 15B THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2017, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION. AVAIL OF GOV DOCS, CONFLICT OF INTEREST POLICY, & FIN STMTS TO GEN PUBLIC FORM 990, PART VI, LINE 19 KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST. ADDITNL DETAIL ON EVENT PRODUCTION EXPENSES INCLUDED ON OTHER EXP FORM 990, PART IX, LINE 24 KOMEN PAYS 50% OF THE COST OF ALL T-SHIRTS FOR THE 125 SUSAN G. KOMEN RACE FOR THE CURE EVENTS CONDUCTED BY THE KOMEN AFFILIATES DURING THE FISCAL YEAR. OTHER CHANGES IN NET ASSETS OR FUND BALANCES FORM 990, PART XI, LINE 9 RESCINDED GRANTS $2,093,947 AFFILIATE RACE SERIES DIRECT BENEFIT $ 939,930 ------------ TOTAL $3,033,877 ============